| Angela Cain, MS ATC, PTA | |
|
2519 Cove Ave, La Grande, OR 97850-3910 | |
| (541) 962-0830 | |
| Not Available |
| Full Name | Angela Cain |
|---|---|
| Gender | Female |
| Speciality | Specialist/technologist - Athletic Trainer |
| Location | 2519 Cove Ave, La Grande, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306204409 | NPI | - | NPPES |
| 9957 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 9957 (Oregon) | Secondary |
| 2255A2300X | Specialist/technologist - Athletic Trainer | 2000017382 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Cain, MS ATC, PTA 1022 Y Ave, La Grande, OR 97850-2749 Ph: (541) 350-3431 | Angela Cain, MS ATC, PTA 2519 Cove Ave, La Grande, OR 97850-3910 Ph: (541) 962-0830 |
News Archive
Oral healthcare is severely affected all over the world by the Covid-19 (SARS-CoV-2) pandemic because of the risk implied for both dental professionals and patients.
Patients with heart failure who felt socially isolated were much more likely to die or be hospitalized than more socially connected patients, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.
Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
Kaiser Health News provides a fresh take on health policy developments with "Aerodynamic Drag" by Lisa Benson.
› Verified 7 days ago